Novavax (NVAX) Set to Announce Earnings on Wednesday

Novavax (NASDAQ:NVAX) is scheduled to release its earnings data after the market closes on Wednesday, August 7th. Analysts expect Novavax to post earnings of ($1.61) per share for the quarter.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($2.20) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.40) by $0.20. The business had revenue of $3.98 million during the quarter, compared to analyst estimates of $4.80 million. During the same period in the prior year, the firm earned ($2.80) EPS. On average, analysts expect Novavax to post $-6 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Shares of NVAX traded down $0.22 during mid-day trading on Friday, hitting $4.32. The company’s stock had a trading volume of 91,569 shares, compared to its average volume of 489,501. The company has a 50-day moving average of $5.01. The company has a market cap of $101.39 million, a PE ratio of -0.43 and a beta of 2.23. Novavax has a fifty-two week low of $4.07 and a fifty-two week high of $51.60.

Several brokerages have recently issued reports on NVAX. HC Wainwright reaffirmed a “positive” rating and issued a $12.00 price objective (up previously from $10.00) on shares of Novavax in a research note on Monday, July 1st. Chardan Capital reaffirmed a “neutral” rating and issued a $7.00 price objective on shares of Novavax in a research note on Friday, May 10th. Cantor Fitzgerald reaffirmed a “hold” rating on shares of Novavax in a research note on Thursday, May 9th. Zacks Investment Research raised shares of Novavax from a “hold” rating to a “buy” rating and set a $8.00 price objective on the stock in a research note on Thursday, May 16th. Finally, ValuEngine raised shares of Novavax from a “sell” rating to a “hold” rating in a research note on Thursday. Two analysts have rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $40.20.

Novavax Company Profile

Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.

Featured Story: Quiet Period

Earnings History for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.